Major stock indexes edged higher Monday to kick off what will be an extraordinarily busy week of news for financial markets.

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Researchers at the University of Colorado Anschutz Medical Campus, Montefiore Einstein Comprehensive Cancer Center (MECCC), ...

A new technology that harnesses artificial intelligence (AI) to analyze mammograms and improve the accuracy of predicting a ...

Celcuity (CELC) announces $175M convertible notes and $38/share stock offerings to raise $248.7M for corporate needs.

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – The average age of cancer patients is getting younger, as experts are ...

Researchers at the University of Colorado Anschutz Medical Campus, Montefiore Einstein Comprehensive Cancer Center (MECCC), and Utrecht University have found the first direct evidence that common ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary - The average age of cancer patients is getting younger, ...

July brought major breast cancer updates, and CURE is sharing the latest, as recent developments underscore how quickly the landscape continues to evolve.

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...